The availability of FRCs of basal insulin (BI) and GLP‐1RAs offers a simplified option to advance therapy in T2DM to further improve glycaemic control, lower body weight without increasing, even lowering, the risk of hypoglycaemia. The gene discussed is INS; the disease is type 2 diabetes mellitus.